Nine more pharmaceutical manufacturers have signed agreements to sell their products in the United States at prices closer to what other wealthy countries pay, expanding a pricing push that now touches most of the branded drug market. The companies join a list that began building earlier in 2026, and together the agreements mark one of the broadest attempts yet to close the long-standing gap between U.S. drug prices and prices abroad.
For older Americans managing multiple prescriptions, the practical effect depends heavily on which drugs they take and which plan covers them, since the agreements work through manufacturer pricing commitments rather than a single across-the-board discount.
The most-favored-nation approach is built around a simple comparison: the price a drugmaker charges in the U.S. against the lowest price that same company charges in other wealthy countries for the identical product. American prices for brand-name drugs have long run well above those charged abroad, a gap that has been debated in Washington for decades without a comprehensive fix, which is part of why the growing list of participating manufacturers has drawn attention from both supporters and critics of the approach.
What the Nine New Deals Cover
According to the White House, the nine manufacturers — Alcon, Astellas Pharma, BeOne Medicines, BridgeBio, CSL, Kyowa Kirin, Sun Pharma, Teva Pharmaceuticals and UCB — agreed to most-favored-nation pricing, meaning the U.S. price for their products moves toward the lowest price those companies charge in other developed countries. The agreements were announced August 31, 2026, and cover both existing products and any new medicines the companies bring to market going forward.
Free Medicare route finder: Help with Medicare costs runs through several separate programs, and each one uses a different form. Find the right one with the free route finder.
Free download from RetireShield. Getting it also signs you up for the free Retirement Money Brief, a weekday email. Unsubscribe anytime.
How This Fits the Broader Pricing Push
These nine agreements bring the total number of manufacturers with most-favored-nation arrangements to 26, which the administration says now represents roughly 89 percent of the U.S. branded prescription drug market. A legal analysis from Duane Morris notes that the expanded roster builds on agreements struck earlier in the year with larger manufacturers, and that the newest nine companies also committed collectively to invest at least $19.6 billion in U.S. manufacturing.
What It Means for Medicaid and New Drugs
The agreements extend beyond Medicare. Under the terms described by the administration, every state Medicaid program gains access to the most-favored-nation prices on the nine companies’ products, and the pricing commitment applies automatically to any new innovative medicine those manufacturers launch in the future rather than requiring a fresh negotiation each time. That structure is meant to prevent the kind of price gap that has historically opened up as soon as a new brand-name drug reaches the market.
The nine companies in this latest round span generic and specialty manufacturers as well as branded drugmakers, a broader mix than the earlier rounds of agreements that focused on a smaller number of the largest branded manufacturers. The administration has framed the growing roster as evidence the approach can scale across the industry rather than remain limited to a handful of headline agreements.
Why Some Advocates Are Watching the Fine Print
Not every reaction has been uncritical. Patients For Affordable Drugs, a nonprofit that tracks drug-pricing policy, has pressed for more detail on how the voluntary agreements are enforced and how quickly the lower prices reach individual patients rather than simply showing up in list-price benchmarks. The agreements are pricing commitments between the government and manufacturers, not a change to what any individual Part D plan charges at the pharmacy counter, so the timeline for a specific enrollee to see a lower cost still runs through their own plan’s formulary and cost-sharing rules.
That distinction is not a reason to dismiss the agreements, but it is a reason to treat them as one part of a larger pricing picture rather than an immediate discount. Enrollees are likely to see the effect show up gradually, through plan pricing and formulary decisions made over the coming enrollment cycles rather than a single visible change at any one pharmacy visit.
A Pricing Deal Seniors Won’t See on a Receipt
A manufacturer agreement signed in Washington does not automatically show up as a smaller number at a local pharmacy, and the space between a pricing announcement and an actual lower copay is where most Part D enrollees lose track of what they are owed. Sorting out whether a specific drug’s price has actually moved takes the same paperwork as any other coverage question — deductible tracking, formulary tiers and appeal rights included.
The Medicare Cost & Coverage Protection Kit is a 10-page kit with 51 state Medicare cost-help packs and a medication and cost tracker built for following prices drug by drug.
Compare costs using The Medicare Cost & Coverage Protection Kit.
This article was written with AI assistance and reviewed by The Financial Wire editorial team before publication.
David M. Keller is a finance writer based in Columbus, Ohio, covering personal finance and consumer-focused economic topics. He earned his degree in journalism from Ohio University and began his career reporting on local business and economic trends for a regional media outlet. Since then, he has contributed to a variety of online publications, focusing on clear, practical coverage of topics such as cost of living, debt, and everyday financial decision-making.
